恒瑞医药(600276.SH)：1类创新药SHR-1918注射液药品上市许可申请获受理并纳入优先审评程序

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1: Product Development - SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), aimed at reducing serum triglycerides (TG) and LDL-C levels [1] - The total R&D investment for the SHR-1918 injection project has reached approximately 242.2 million yuan (unaudited) [1] Group 2: Market Context - The only other drug targeting the same pathway is Regeneron's EVKEEZA® (evinacumab-dgnb), which has been approved and is projected to generate global sales of approximately $216 million by 2025 [1]